The Korea Times close
National
  • Politics
  • Diplomacy
  • Defense
  • Labor & Environment
  • Law & Crime
  • Health & Welfare
  • Embassy
  • Seoul & Provinces
  • Education
  • Foreign Communities
  • Obituaries
  • Multicultural Youth Award
Biz & Tech
  • Auto
  • IT
  • Game
  • Manufacturing
  • Retail & Food
  • Energy
  • Construction
  • Airlines
Finance
  • Policies
  • Economy
  • Markets
  • Banks
  • Non-banks
  • Economic Essay Contest
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to the Editor
Lifestyle
  • Arts
  • Books
  • Travel & Cuisine
  • Trend
  • Fashion
  • Around Town
  • Fortune Telling
Entertainment
  • K-pop
  • K-dramas & Shows
  • Movies
  • Music
  • Performances
  • Asia Model Festival
Sports
  • Football
  • Golf
  • Baseball
  • Other Sports
World
  • Asia Pacific
  • Americas
  • Europe & Africa
  • SCMP
Video
  • On the Spot
  • Feature
  • News
Photos
  • Photo News
  • Darkroom
Community
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
  • The Korea Times
  • search
  • Site Map
  • E-paper
  • Subscribe
  • Register
  • LogIn
search close
Biz & Tech
  • Auto
  • IT
  • Game
  • Manufacturing
  • Retail & Food
  • Energy
  • Construction
  • Airlines
Tue, January 19, 2021 | 07:52
Retail & Food
Korean drug makers make strides in fighting hardly-cured diseases
Posted : 2020-05-22 16:31
Updated : 2020-05-23 09:59
Mail
Print Preview
Font Size Up
Font Size Down
A Celltrion Pharm plant in Cheongju, North Chungcheong Province / Courtesy of Celltrion Pharm
A Celltrion Pharm plant in Cheongju, North Chungcheong Province / Courtesy of Celltrion Pharm

By Nam Hyun-woo

Korean pharmaceutical companies are fighting hardly cured viruses such as the coronavirus and HIV to fill the possible vacuum in the global procurement market stemming from lockdowns on global drug makers.

According to Celltrion Pharm, a pharmaceutical unit of biotech group Celltrion, it will set up a manufacturing line exclusively for Celltrion's HIV treatment CT-G7 at its plant in Cheongju, North Chungcheong Province.

After setting up the new line, the company will operate the plant around the clock, as well as increasing the researching and manufacturing workforces by 15 percent.

The decision appears to be the company's strategy to exploit a possible vacuum in the global HIV treatment procurement market in the near future, as drug makers in India, which are major suppliers of chemical drugs for the global market, suffer lockdowns due to the COVID-19 outbreak. The company said Indian pharmaceutical firms' plant operation rate averaged 30 percent.

CT-G7, earlier known as CT-G07, is a three-drug-in-one-tablet HIV treatment developed by Celltrion, which won a tentative approval from the U.S. Food and Drug Administration (FDA) in April. The FDA in March conducted an on-site inspection of the Cheongju plant and observed no violation.

According to Clinton Health Access Initiative, the global HIV treatment market is valued at 1.2 trillion won ($969.5 million), and Celltrion Group believes CT-G7 will occupy at least 10 percent of the market to post 120 billion won in sales annually.

Since global procurement agencies are focusing on the stable supply of HIV treatments in the wake of the COVID-19 pandemic, Celltrion Pharm said it is seeking to raise the market share to 20 percent.

Recently, Korean pharmaceutical firms are making strides in the world's battle against costly and deadly diseases. Their efforts to improve their presence in the global market came as a response to the country's fast recovery from the COVID-19 outbreak.

Celltrion is currently developing an antibody drug stemming from cured COVID-19 patients' blood samples after earmarking 20 billion won for R&D. With clinical tests scheduled for mid-July, Celltrion Chairman Seo Jung-jin said the company will prioritize speed rather than profitability.

GC Pharma, which is also developing a blood plasma therapy for COVID-19 ― GC5131A ― recently decided to provide its therapy for free to Korean patients, shouldering all costs for development and distribution.

"The drug for the unprecedented pandemic should fully serve the purpose of public healthcare," GC Pharma CEO Huh Eun-chul said.



Emailnamhw@koreatimes.co.kr Article ListMore articles by this reporter









 
WooriBank
 
  • Man jumps to death inside shopping mall in Seoul
  • Foreign residents left out of digital-oriented banking service
  • Samsung heir Lee Jae-yong imprisoned again
  • Heavy snow advisory issued for Seoul
  • Lee's jail sentence casts cloud on Samsung's business
  • Moon calls on Biden to move forward from Singapore agreement with North Korea
  • LG Energy Solution IPO could test Citigroup's friendship with SK
  • Shake Shack introduces Korean-inspired chicken sandwich in US
  • Nosediving movie theater business hampers CGV sale plan
  • New virus cases at almost 2-month low on fewer tests, infections slowdown
  • Music publishing sector booming with high-profile sales Music publishing sector booming with high-profile sales
  • Boy group Cravity features in Airbnb's 'Inside K-pop' program Boy group Cravity features in Airbnb's 'Inside K-pop' program
  • Selena Gomez: Big Tech 'cashing in from evil' Selena Gomez: Big Tech 'cashing in from evil'
  • Netflix to roll out more original series based on Korean webtoons in 2021 Netflix to roll out more original series based on Korean webtoons in 2021
  • 'The Uncanny Counter' writer leaves show despite soaring ratings 'The Uncanny Counter' writer leaves show despite soaring ratings
DARKROOM
  • Second Trump impeachment

    Second Trump impeachment

  • Pro-Trump rioters breach the US Capitol

    Pro-Trump rioters breach the US Capitol

  • Our children deserve better (Part 2)

    Our children deserve better (Part 2)

  • Migrants hard hit by COVID-19: UN migration agency

    Migrants hard hit by COVID-19: UN migration agency

  • Happy New Year 2021

    Happy New Year 2021

WooriBank
  • About Korea Times
  • CEO Message
  • Times History
  • Content Sales
  • Media Kit
  • Contact Us
  • Location
  • Privacy Statement
  • Terms of Service
  • Mobile Service
  • RSS Service
  • Ombudsman
  • hankookilbo
  • Dongwha Group
  • Code of Ethics
Copyright